Developing novel product candidates for cancer & respiratory viral diseases
A clinical stage company aiming to address unmet medical needs in cancer and respiratory viral diseases
Traws Pharma leverages broad and deep expertise in small molecule chemistry, artificial intelligence and machine learning, rational drug design & streamlined development to deliver innovative medicines. We target critical threats to human health, aiming to overcome problems caused by acquired resistance to current medications, with an additional focus on vulnerable populations
Traws Pharma Announces New Employee Inducement Grants
Traws Pharma, Inc. (Nasdaq: TRAW, “Traws”, the “Company”) today announced it has granted equity awards to new employees who joined Traws in connection with the recent acquisition of Trawsfynydd Therapeutics, Inc. by Onconova Therapeutics, Inc. (the “Merger”).
Onconova Therapeutics, Inc. And Trawsfynydd Therapeutics, Inc. Announce Business Combination To Form Traws Pharma, Inc, A Best-In-Class Virology And Oncology Company
Closing cash balance of approximately $28 million expected from concurrent private placement led by OrbiMed and Torrey Pines Investment.